Skip Navigation


Annals of Oncology Advance Access originally published online on April 16, 2007
Annals of Oncology 2007 18(5):960-961; doi:10.1093/annonc/mdm115
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/5/960    most recent
mdm115v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ottaiano, A
Right arrow Articles by Caraglia, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ottaiano, A
Right arrow Articles by Caraglia, M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

letters to the editor

A multidisciplinary approach is required to increase the quality of phase II/III clinical studies on biotherapies in oncology

The first 10% of the full text of this article appears below.

We have previously published an appropriate score in order to evaluate the quality of phase II studies on biochemotherapy validated through the screening of 334 papers published from 1998 to 2002 [1. . . [Full Text of this Article]

A Ottaiano1, A Budillon2, N Normanno2, VR Iaffaioli1 and M Caraglia2,*

1 Unit of 1B Medical Oncology
2 Experimental Pharmacology, National Cancer Institute Fondazione ‘G. Pascale’, Via M. Semmola 80131, Naples, Italy

* (E-mail: Michele.caraglia@fondazionepascale.it)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?